Payment overview · 2025
General Payments
$2,007.24
106 reported records · 27 companies
Healthcare provider profile · identity verified
Naveed Mahfooz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARO, MI · NPI 1780639450
Verified facts
What the public records show
CMS Open Payments records show Naveed Mahfooz, MD received $2,007.24 in general payments during 2025 across 106 reported records.
Amgen Inc. accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Farxiga, Jardiance, Mounjaro, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 357 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $311.58 | 15.5% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $219.83 | 10.9% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $191.09 | 9.5% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $163.53 | 8.2% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $157.66 | 7.8% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.60 | 7.0% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.31 | 6.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.12 | 5.9% | 8 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.06 | 3.3% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $64.09 | 3.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.39 | 2.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $45.24 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.56 | 2.0% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $37.27 | 1.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.86 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.85 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.49 | 1.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.34 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.75 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.24 | 1.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.25 | 1.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.35 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.09 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.76 | 0.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.62 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.70 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.61 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,993.48 | 105 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $282.97 | 13 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $219.83 | 11 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $191.09 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $169.54 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $163.53 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $142.04 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $142.04 | 9 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $102.29 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.16 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.16 | 6 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $66.06 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 174 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 612 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 129 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 147 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
152 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
221 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
174 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
612 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
147 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
323 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
612 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
357 | 60 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
129 | 15 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
129 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3856 | 343 |
| Levothyroxine Sodium | Levothyroxine Sodium | 3406 | 272 |
| Furosemide | Furosemide | 2319 | 303 |
| Eliquis | Apixaban | 1643 | 153 |
| Potassium Chloride | Potassium Chloride | 1611 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 1609 | 210 |
| Omeprazole | Omeprazole | 1586 | 203 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1504 | 150 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1466 | 167 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1415 | 166 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1335 | 230 |
| Lisinopril | Lisinopril | 1227 | 153 |
| Famotidine | Famotidine | 1206 | 71 |
| Gabapentin | Gabapentin | 1204 | 176 |
| Metformin Hcl | Metformin Hcl | 1193 | 130 |
| Duloxetine Hcl | Duloxetine Hcl | 909 | 85 |
| Sertraline Hcl | Sertraline Hcl | 797 | 80 |
| Losartan Potassium | Losartan Potassium | 788 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 746 | 123 |
| Allopurinol | Allopurinol | 678 | 82 |
| Ropinirole Hcl | Ropinirole Hcl | 678 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 647 | 96 |
| Prednisone | Prednisone | 631 | 273 |
| Donepezil Hcl | Donepezil Hcl | 615 | 68 |
| Jardiance | Empagliflozin | 612 | 65 |
| Carvedilol | Carvedilol | 610 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 603 | 93 |
| Alprazolam | Alprazolam | 597 | 125 |
| Simvastatin | Simvastatin | 555 | 83 |
| Bethanechol Chloride | Bethanechol Chloride | 553 | 36 |
| Bumetanide | Bumetanide | 524 | 44 |
| Spironolactone | Spironolactone | 521 | 51 |
| Montelukast Sodium | Montelukast Sodium | 482 | 58 |
| Baclofen | Baclofen | 466 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 439 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 421 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 410 | 41 |
| Levetiracetam | Levetiracetam | 409 | 42 |
| Trazodone Hcl | Trazodone Hcl | 403 | 56 |
| Midodrine Hcl | Midodrine Hcl | 365 | 36 |
| Olanzapine | Olanzapine | 364 | 19 |
| Trulicity | Dulaglutide | 357 | 60 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 356 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 96 |
| Finasteride | Finasteride | 331 | 50 |
| Xarelto | Rivaroxaban | 323 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 316 | 37 |
| Lorazepam | Lorazepam | 311 | 68 |
| Mirtazapine | Mirtazapine | 308 | 36 |
| Ezetimibe | Ezetimibe | 305 | 27 |
| Fenofibrate | Fenofibrate | 303 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 301 | 34 |
| Memantine Hcl | Memantine Hcl | 300 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 299 | 55 |
| Tramadol Hcl | Tramadol Hcl | 292 | 77 |
| Meloxicam | Meloxicam | 286 | 48 |
| Sucralfate | Sucralfate | 281 | 35 |
| Gemfibrozil | Gemfibrozil | 275 | suppressed |
| Azithromycin | Azithromycin | 272 | 152 |
| Ibuprofen | Ibuprofen | 270 | 72 |
| Celecoxib | Celecoxib | 258 | 68 |
| Oxybutynin Chloride | Oxybutynin Chloride | 256 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 254 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 252 | 21 |
| Divalproex Sodium | Divalproex Sodium | 245 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 102 |
| Risperidone | Risperidone | 232 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 228 | 24 |
| Myrbetriq | Mirabegron | 221 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 212 | 29 |
| Buspirone Hcl | Buspirone Hcl | 206 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 203 | 58 |
| Warfarin Sodium | Warfarin Sodium | 197 | 27 |
| Cephalexin | Cephalexin | 194 | 135 |
| Vascepa | Icosapent Ethyl | 187 | suppressed |
| Glipizide Er | Glipizide | 185 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 184 | suppressed |
| Atenolol | Atenolol | 183 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 181 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 74 |
| Farxiga | Dapagliflozin Propanediol | 174 | 19 |
| Alendronate Sodium | Alendronate Sodium | 171 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 170 | 114 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 170 | 40 |
| Propranolol Hcl | Propranolol Hcl | 166 | suppressed |
| Glipizide | Glipizide | 158 | 22 |
| Calcitriol | Calcitriol | 154 | 15 |
| Linzess | Linaclotide | 152 | 32 |
| Clonazepam | Clonazepam | 150 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 149 | 81 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 147 | 28 |
| Desmopressin Acetate | Desmopressin Acetate | 145 | suppressed |
| Januvia | Sitagliptin Phosphate | 144 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 141 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 52 |
| Lovastatin | Lovastatin | 141 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 138 | 34 |
| Primidone | Primidone | 138 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 133 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 129 | suppressed |
| Rexulti | Brexpiprazole | 129 | 15 |
| Bupropion Xl | Bupropion Hcl | 128 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 125 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 124 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 117 | 21 |
| Fluconazole | Fluconazole | 116 | 71 |
| Ondansetron Odt | Ondansetron | 116 | 36 |
| Colchicine | Colchicine | 115 | 13 |
| Mounjaro | Tirzepatide | 115 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 115 | 47 |
| Ozempic | Semaglutide | 109 | 29 |
| Topiramate | Topiramate | 107 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 22 |
| Nuplazid | Pimavanserin Tartrate | 101 | suppressed |
| Torsemide | Torsemide | 100 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 98 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 37 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 96 | 23 |
| Nabumetone | Nabumetone | 95 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 95 | 39 |
| Nystatin | Nystatin | 93 | 58 |
| Diazepam | Diazepam | 90 | 19 |
| Leflunomide | Leflunomide | 90 | suppressed |
| Nifedipine Er | Nifedipine | 90 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 85 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 85 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 83 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 83 | suppressed |
| Aripiprazole | Aripiprazole | 81 | 15 |
| Entresto | Sacubitril/Valsartan | 80 | 15 |
| Enulose | Lactulose | 80 | 12 |
| Methotrexate | Methotrexate Sodium | 79 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 77 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 77 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 76 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 26 |
| Fluphenazine Hcl | Fluphenazine Hcl | 75 | suppressed |
| Niacin Er | Niacin | 75 | suppressed |
| Amantadine | Amantadine Hcl | 74 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 74 | suppressed |
| Latanoprost | Latanoprost | 71 | 13 |
| Chlorthalidone | Chlorthalidone | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 70 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 22 |
| Prazosin Hcl | Prazosin Hcl | 66 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 64 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 64 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 63 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 62 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 23 |
| Novolog Flexpen | Insulin Aspart | 61 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | 17 |
| Digoxin | Digoxin | 60 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 60 | suppressed |
| Novolog | Insulin Aspart | 59 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Cilostazol | Cilostazol | 57 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 11 |
| Glimepiride | Glimepiride | 56 | 16 |
| Pregabalin | Pregabalin | 56 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 54 | 13 |
| Folic Acid | Folic Acid | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | 15 |
| Lacosamide | Lacosamide | 53 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 52 | 11 |
| Mupirocin | Mupirocin | 51 | 30 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | suppressed |
| Paliperidone Er | Paliperidone | 50 | suppressed |
| Rybelsus | Semaglutide | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | 22 |
| Brilinta | Ticagrelor | 48 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 48 | suppressed |
| Humalog | Insulin Lispro | 48 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 48 | 18 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 48 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Gemtesa | Vibegron | 46 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 45 | 13 |
| Verapamil Er | Verapamil Hcl | 45 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 12 |
| Metolazone | Metolazone | 44 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Bupropion Hcl | Bupropion Hcl | 43 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Glycopyrrolate | Glycopyrrolate | 43 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 20 |
| Morphine Sulfate | Morphine Sulfate | 43 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 14 |
| Ranolazine Er | Ranolazine | 43 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 43 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 41 | 19 |
| Azathioprine | Azathioprine | 40 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 39 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 39 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Nitroglycerin | Nitroglycerin | 38 | 28 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 11 |
| Enalapril Maleate | Enalapril Maleate | 37 | 11 |
| Lactulose | Lactulose | 37 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 11 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 36 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 12 |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 33 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 24 |
| Rivastigmine | Rivastigmine Tartrate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 26 |
| Cefdinir | Cefdinir | 32 | 19 |
| Nyamyc | Nystatin | 32 | 12 |
| Verquvo | Vericiguat | 32 | suppressed |
| Xifaxan | Rifaximin | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 31 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 31 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | 11 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Nystop | Nystatin | 29 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 17 |
| Scopolamine | Scopolamine | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | 12 |
| Budesonide Dr | Budesonide | 27 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 27 | suppressed |
| Ofloxacin | Ofloxacin | 27 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Cholestyramine Light | Cholestyramine | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 15 |
| Entacapone | Entacapone | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 13 |
| Vancomycin Hcl | Vancomycin Hcl | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Atropine Sulfate | Atropine Sulfate | 25 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 13 |
| Estradiol | Estradiol | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Silodosin | Silodosin | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Tiotropium Bromide | Tiotropium Bromide | 20 | suppressed |
| Bicalutamide | Bicalutamide | 19 | suppressed |
| Bimatoprost | Bimatoprost | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Matzim La | Diltiazem Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 12 |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Levocarnitine | Levocarnitine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pacerone | Amiodarone Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,007.24 · 106 records | Amgen Inc. | Briviact, CAPLYTA, CAPVAXIVE, CREXONT, ENTYVIO, EOHILIA, EVENITY, FANAPT, FARXIGA, FUROSCIX, GVOKE HYPOPEN, INSPIRE, JARDIANCE, KEVEYIS, KISUNLA, Kerendia, Korlym, MOUNJARO, NUZYRA, Nayzilam, OTEZLA, Ohtuvayre, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, VERQUVO, VRAYLAR, Veozah, Vest Therapy Und, WATCHMAN FLX, ZENPEP, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error